The long-term objective of this research is to understand the functional basis for the expression of apolipoprotein (apo) E in peripheral tissues. ApoE is important for regulating systemic cholesterol transport and metabolism. Among the plasma apolipoproteins, apoE is unusual in being expressed in many tissues and is involved in cellular processes and diseases that are independent of systemic lipoprotein metabolism. This proposal has two primary objectives. The first is to define the mechanisms by which low-levels of plasma apoE suppress atherosclerotic lesion development. Previous studies showed that levels of transgenic apoE too low to correct hypercholesterolemia in apoE-deficient mice still blocked aortic lesion formation. The second goal is to determine how localized apoE expression in adrenocortical cells regulates the utilization of cholesterol for steroid production. These studies employ apoE-deficient mouse lines that have been engineered to express different levels of transgenic apoE selectively in the adrenal gland. The proposal has 3 Aims.
Aim 1 has three goals focused on how low-levels (equal to approximately 10[-8]M) of apoE alter the initial stages of lesion formation. Goal 1 will use quantitative real-time PCR to monitor expression of a set of candidate genes during initial stages of leukocyte recruitment to the vascular wall. Goal 2 will determine whether signaling pathways for platelet derived growth factor or LFA-1 or those involving the transcription factor NFkappaB are activated in vascular cells at early stages, and whether low-level apoE alters this activation. Goal 3 will test which receptors of the LDL receptor family are important for the atheroprotective effects of low-level apoE.
Aim 2 will define mechanisms by which apoE alters cholesterol utilization for steroid production in the adrenal gland in vivo. Goal 1 will use immunocytochemical approaches to evaluate the variegated pattern of transgenic apoE expression in the adrenal cortex and to test the effect of localized apoE on the expression of key proteins involved in the provision of substrate cholesterol to the steroidogenic pathway. Goal 2 will test which receptors of the LDL receptor family are important for the effects of apoE in adrenocortical cells.
Aim 3 has collaborative projects to test the effects of low-level apoE on neointimal formation after arterial injury and on regression of atherosclerotic lesions. These studies will provide new mechanistic information about actions of apoE on cholesterol metabolism and atherosclerosis.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL032868-22
Application #
7097403
Study Section
Atherosclerosis and Inflammation of the Cardiovascular System Study Section (AICS)
Program Officer
Wassef, Momtaz K
Project Start
1984-06-01
Project End
2008-06-30
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
22
Fiscal Year
2006
Total Cost
$539,729
Indirect Cost
Name
State University New York Stony Brook
Department
Pharmacology
Type
Schools of Medicine
DUNS #
804878247
City
Stony Brook
State
NY
Country
United States
Zip Code
11794
Ma, Yanqing; Malbon, Craig C; Williams, David L et al. (2008) Altered gene expression in early atherosclerosis is blocked by low level apolipoprotein E. PLoS One 3:e2503
Zhao, Yue; Thorngate, Fayanne E; Weisgraber, Karl H et al. (2005) Apolipoprotein E is the major physiological activator of lecithin-cholesterol acyltransferase (LCAT) on apolipoprotein B lipoproteins. Biochemistry 44:1013-25
Mann, Karen M; Thorngate, Fayanne E; Katoh-Fukui, Yuko et al. (2004) Independent effects of APOE on cholesterol metabolism and brain Abeta levels in an Alzheimer disease mouse model. Hum Mol Genet 13:1959-68
Wientgen, Hilke; Thorngate, Fayanne E; Omerhodzic, Sabina et al. (2004) Subphysiologic apolipoprotein E (ApoE) plasma levels inhibit neointimal formation after arterial injury in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 24:1460-5
Thorngate, Fayanne E; Yancey, Patricia G; Kellner-Weibel, Ginny et al. (2003) Testing the role of apoA-I, HDL, and cholesterol efflux in the atheroprotective action of low-level apoE expression. J Lipid Res 44:2331-8
Temel, Ryan E; Parks, John S; Williams, David L (2003) Enhancement of scavenger receptor class B type I-mediated selective cholesteryl ester uptake from apoA-I(-/-) high density lipoprotein (HDL) by apolipoprotein A-I requires HDL reorganization by lecithin cholesterol acyltransferase. J Biol Chem 278:4792-9
Thorngate, Fayanne E; Strockbine, Penelope A; Erickson, Sandra K et al. (2002) Altered adrenal gland cholesterol metabolism in the apoE-deficient mouse. J Lipid Res 43:1920-6
Swarnakar, S; Beers, J; Strickland, D K et al. (2001) The apolipoprotein E-dependent low density lipoprotein cholesteryl ester selective uptake pathway in murine adrenocortical cells involves chondroitin sulfate proteoglycans and an alpha 2-macroglobulin receptor. J Biol Chem 276:21121-8
DeMattos, R B; Rudel, L L; Williams, D L (2001) Biochemical analysis of cell-derived apoE3 particles active in stimulating neurite outgrowth. J Lipid Res 42:976-87
Thorngate, F E; Rudel, L L; Walzem, R L et al. (2000) Low levels of extrahepatic nonmacrophage ApoE inhibit atherosclerosis without correcting hypercholesterolemia in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 20:1939-45

Showing the most recent 10 out of 55 publications